1. Home
  2. TRX vs RVPH Comparison

TRX vs RVPH Comparison

Compare TRX & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TRX Gold Corporation

TRX

TRX Gold Corporation

HOLD

Current Price

$0.90

Market Cap

228.9M

Sector

N/A

ML Signal

HOLD

Logo Reviva Pharmaceuticals Holdings Inc.

RVPH

Reviva Pharmaceuticals Holdings Inc.

HOLD

Current Price

$0.63

Market Cap

71.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRX
RVPH
Founded
1990
2006
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
228.9M
71.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TRX
RVPH
Price
$0.90
$0.63
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
6
Target Price
$1.25
$3.33
AVG Volume (30 Days)
1.4M
4.4M
Earning Date
01-13-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.00
N/A
Revenue
$57,613,000.00
N/A
Revenue This Year
$28.16
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$363.98
N/A
Revenue Growth
39.98
N/A
52 Week Low
$0.27
$0.25
52 Week High
$0.89
$2.95

Technical Indicators

Market Signals
Indicator
TRX
RVPH
Relative Strength Index (RSI) 72.25 54.51
Support Level $0.82 $0.60
Resistance Level $0.89 $0.77
Average True Range (ATR) 0.05 0.06
MACD 0.02 0.01
Stochastic Oscillator 98.21 49.46

Price Performance

Historical Comparison
TRX
RVPH

About TRX TRX Gold Corporation

TRX Gold Corp is a mineral resource company. It is engaged in the acquisition of interests and the exploration of natural resource properties. Its mineral properties are located in the United Republic of Tanzania. The company's main area of interest has been in the exploration and development of gold properties. It is focused on the Buckreef Gold Project which comprises five prospects, namely Buckreef, Bingwa, Tembo, Eastern Porphyry, and Buziba.

About RVPH Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.

Share on Social Networks: